×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KYMR – kymera therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KYMR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/6
05:34 pm
kymr
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Low
Report
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
11/6
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
11/5
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
11/4
11:22 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
11/4
06:23 am
kymr
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]
11/1
03:39 pm
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a "buy" rating on the stock.
11/1
11:55 am
kymr
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
11/1
11:27 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $53.00 price target on the stock, down previously from $54.00.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $53.00 price target on the stock, down previously from $54.00.
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
07:30 am
KYMR
kymera therapeutics, inc.
BEAT
Report
1.5%
kymera therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:32 pm
kymr
Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Low
Report
Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
11/14
01:24 pm
kymr
Form SC 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
09:30 am
kymr
Form SC 13G/A Kymera Therapeutics, Filed by: Avoro Capital Advisors LLC
Medium
Report
Form SC 13G/A Kymera Therapeutics, Filed by: Avoro Capital Advisors LLC
11/12
10:33 am
kymr
Form SC 13G Kymera Therapeutics, Filed by: FMR LLC
Low
Report
Form SC 13G Kymera Therapeutics, Filed by: FMR LLC
11/8
10:53 am
kymr
Form SC 13G/A Kymera Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A Kymera Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
10/31
08:14 am
kymr
Form S-3ASR Kymera Therapeutics,
Low
Report
Form S-3ASR Kymera Therapeutics,
10/31
07:46 am
kymr
Form 10-Q Kymera Therapeutics, For: Sep 30
Low
Report
Form 10-Q Kymera Therapeutics, For: Sep 30
10/31
07:40 am
kymr
Form 8-K Kymera Therapeutics, For: Oct 31
Low
Report
Form 8-K Kymera Therapeutics, For: Oct 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: